Compare ADMA Biologics Inc (ADMA) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs QUALCOMM, Inc. — how do they compare? ADMA Biologics Inc trades at $9.9 (market cap $2.22B), while QUALCOMM, Inc. trades at $161.3 (market cap $170.81B). The key difference: QUALCOMM, Inc. is far larger — about 76.9× ADMA Biologics Inc's market cap, and QUALCOMM, Inc. pays a 2.26% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | QCOM | |
|---|---|---|
Market Cap | $2.22B | $170.81B |
Sector | Health | Technology |
52-Week High | $20.38 | $251.10 |
52-Week Low | $7.60 | $124.07 |
Enterprise Value | $2.29B | $177.78B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
Qualcomm (QCOM) trades at $162.17, down 3.39% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong revenue of $44.28B in 2025 but saw net income decline to $5.54B, reflecting margin pressures. Recent news highlights Qualcomm's AI and data center expansion efforts, including the 'Dragonfly' AI platform announcement at COMPUTEX 2026, while facing increased competition from Nvidia in the PC chip market.
The outlook remains balanced with a consensus price target of $200.56 suggesting 24% upside, but near-term headwinds include smartphone market softness and margin compression. Long-term growth drivers in automotive and AI inference markets provide opportunity, though execution risks and competitive threats from chip rivals pose challenges for shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
